Article summary
A highly anticipated public hearing at the FDA focused on questions about credentialing providers of psychedelic-assisted therapies, patient safety, data standardization, and equitable access to emerging therapies. The post FDA Holds Historic Public Hearing on Psychedelic Therapies first appeared on Lucid News.
Continue to the original publication for the complete article.